Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?
- PMID: 15919198
- DOI: 10.1016/j.ejca.2005.03.018
Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?
Abstract
Over-expression of the epidermal growth factor receptor (EGFR) in tumours is associated with aggressive disease and poor clinical prognosis. In theory, the EGFR status of a tumour provides an indication of the likelihood of response to EGFR-targeted therapy. However, the clinical data do not support a relationship between EGFR expression and response to EGFR-targeted therapies cetuximab, gefitinib and erlotinib. Recently, patients who appear to lack EGFR expression have been shown to respond to cetuximab. Possible causes for this paradox include false negative results due to a lack of sensitivity in the detection system, heterogeneity of EGFR expression within the tumour and specific mutations that mediate response to the tyrosine kinase inhibitors. Immunohistochemistry is the most reliable assay for EGFR expression but its interpretation is confounded by the lack of non-standard techniques. Other approaches for measuring EGFR expression can be considered at best exploratory at this point. Further work is needed to identify how EGFR contributes to carcinogenic and metastatic processes. As tumours that appear to be EGFR negative can respond to cetuximab, there is some doubt as to the usefulness of immunohistochemistry as a screen to select patients for treatment. Histopathology will continue to be essential for unravelling the role of this enigmatic molecule and refining its status as a legitimate target in cancer therapy.
Similar articles
-
Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.Anticancer Drugs. 2009 Nov;20(10):851-5. doi: 10.1097/CAD.0b013e3283330590. Anticancer Drugs. 2009. PMID: 19826350 Review.
-
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.J Clin Oncol. 2006 Sep 1;24(25):4170-6. doi: 10.1200/JCO.2006.07.2587. J Clin Oncol. 2006. PMID: 16943533
-
Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression.Hum Pathol. 2006 Jun;37(6):755-63. doi: 10.1016/j.humpath.2006.02.004. Hum Pathol. 2006. PMID: 16733218
-
EGFR assays in lung cancer.Adv Anat Pathol. 2008 Jul;15(4):241-7. doi: 10.1097/PAP.0b013e31817bf5a9. Adv Anat Pathol. 2008. PMID: 18580100 Review.
-
Epidermal growth factor receptor expression in high-grade osteosarcomas is associated with a good clinical outcome.Clin Cancer Res. 2007 May 15;13(10):2998-3005. doi: 10.1158/1078-0432.CCR-06-2432. Clin Cancer Res. 2007. PMID: 17505002
Cited by
-
Cyclin D1, EGFR, and Akt/mTOR pathway. Potential prognostic markers in localized laryngeal squamous cell carcinoma.Strahlenther Onkol. 2013 Mar;189(3):202-14. doi: 10.1007/s00066-012-0275-0. Epub 2013 Feb 13. Strahlenther Onkol. 2013. PMID: 23400686
-
A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining.Invest New Drugs. 2011 Feb;29(1):167-74. doi: 10.1007/s10637-009-9341-6. Epub 2009 Oct 15. Invest New Drugs. 2011. PMID: 19830388 Clinical Trial.
-
Evaluating Inhibition of the Epidermal Growth Factor (EGF)-Induced Response of Mutant MCF10A Cells with an Acoustic Sensor.Biosensors (Basel). 2012 Nov 13;2(4):448-64. doi: 10.3390/bios2040448. Biosensors (Basel). 2012. PMID: 25586035 Free PMC article.
-
The Development of Positron Emission Tomography Tracers for In Vivo Targeting the Kinase Domain of the Epidermal Growth Factor Receptor.Pharmaceuticals (Basel). 2022 Apr 5;15(4):450. doi: 10.3390/ph15040450. Pharmaceuticals (Basel). 2022. PMID: 35455447 Free PMC article. Review.
-
Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers.Lancet Neurol. 2010 Jul;9(7):717-26. doi: 10.1016/S1474-4422(10)70105-8. Lancet Neurol. 2010. PMID: 20610347 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous